Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2023, the Group had a portfolio of 7 products in clinical development (including 3 in phase III, 3 in phase II and 1 in phase I), and 3 products in preclinical development.

Employees

298

Sector

Biotechnology & Medical Research

Calendar

2025-02-20 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-01-20	697.00 kr	-2.31%	125,225
25-01-17	713.50 kr	+1.93%	226,657
25-01-16	700.00 kr	-0.07%	163,304
25-01-15	700.50 kr	+0.65%	149,562
25-01-14	696.00 kr	-0.43%	213,325

Delayed Quote Nasdaq Copenhagen, January 20, 2025 at 11:20 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart ZEALAND-PHARMA-A-S

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

BBB

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

697.00DKK

Average target price

1,007.64DKK

Spread / Average Target

+44.57%

Consensus

Profit revisions

estimates-change-chart ZEALAND-PHARMA-A-S

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart ZEALAND-PHARMA-A-S

Company calendar

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-01-20 am EST			5-day change	1st Jan Change
697.00 ^DKK	-2.31%		-0.29%	-2.59%

Jan. 13	Zealand Pharma A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 02:15 PM
Jan. 07	Jefferies lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy	FW

Capitalization	49.24B 6.87B 6.6B 6.23B 5.58B 9.83B 592B 10.96B 75.72B 28.06B 244B 25.75B 25.22B 1,069B	P/E ratio 2024 *	-54.2x	P/E ratio 2025 *	178x
Enterprise value	42.12B 5.87B 5.65B 5.33B 4.77B 8.41B 506B 9.38B 64.77B 24B 209B 22.02B 21.57B 914B	EV / Sales 2024 *	121x	EV / Sales 2025 *	20.6x
Free-Float	99.18%	Yield 2024 *	-	Yield 2025 *	-

Zealand Pharma A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 02:15 PM	Jan. 13
Jefferies lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy	Jan. 07	FW
Deutsche Bank lowers target price for Zealand Pharma to 750 Danish kroner (815), reiterates hold	Dec. 23	FW
Zealand Pharma A/S(CPSE:ZEAL) added to OMX Nordic 40 Index	Dec. 22	CI
Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug	Dec. 20	DJ
DNB lowers target price for Zealand Pharma to DKK 1,010 (1,050), reiterates Buy - BN	Dec. 20	FW
Correction: Zealand Pharma Gets US FDA's Complete Response Letter for Short Bowel Syndrome Drug	Dec. 20	MT
FDA wants an additional study from Zealand Pharma for glepaglutide	Dec. 20	FW
BTIG lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy - BN	Dec. 20	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,004 (1,095), reiterates Buy - BN	Dec. 20	FW
Zeland Pharma Gets US FDA's Complete Response Letter for Short Bowel Syndrome Drug	Dec. 20	MT
Zealand Pharma Fails to Get FDA Approval for Short Bowel Syndrome Drug	Dec. 19	MT
Zealand Pharma Falls Short of FDA Approval for Glepaglutide	Dec. 19	DJ

Jefferies lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy	Jan. 07	FW
Deutsche Bank lowers target price for Zealand Pharma to 750 Danish kroner (815), reiterates hold	Dec. 23	FW
DNB lowers target price for Zealand Pharma to DKK 1,010 (1,050), reiterates Buy - BN	Dec. 20	FW
BTIG lowers target price for Zealand Pharma to DKK 1,050 (1,100), reiterates Buy - BN	Dec. 20	FW
Goldman Sachs lowers target price for Zealand Pharma to DKK 1,004 (1,095), reiterates Buy - BN	Dec. 20	FW

Zealand Pharma A/S Stock

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Valuation: Zealand Pharma A/S

Chart: Zealand Pharma A/S

Latest news: Zealand Pharma A/S

Last Transcript: Zealand Pharma A/S

Analysts' recommendations: Zealand Pharma A/S

Press Releases: Zealand Pharma A/S

News in other languages: Zealand Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Zealand Pharma A/S

ETFs: Zealand Pharma A/S

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	Jan. 13	GL
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity	Jan. 07	GL
Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity	Jan. 07	AQ
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th	Jan. 06	GL
Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	Dec. 27	AQ

Les actions en mouvement : Novo Nordisk bien sur mais aussi Idorsia qui s'effondre	Dec. 20
Borse Europa in calo, investitori preoccupati su avvertimento Trump a Ue	Dec. 20
Faucons, vrais doutes	Dec. 20
En direct des marchés : Vinci, Diageo, Crédit Agricole, Fedex, Rio Tinto, Orange, Réalités, Nike…	Dec. 20
Actualización de las fuertes variaciones del día: Continental anuncia buenas noticias; temores en Bayer	24-10-09

1 day	-2.31%
1 week	-0.29%
Current month	-2.59%
1 month	-4.26%
3 months	-13.31%
6 months	-19.33%
Current year	-2.59%

Director	Title	Age	Since
Adam Sinding Steensberg CEO	Chief Executive Officer	51	2022-03-29
Henriette Wennicke DFI	Director of Finance/CFO	-	2022-10-31
David M. Kendall CTO	Chief Tech/Sci/R&D Officer	63	2022-06-01

Manager	Title	Age	Since
Alf Gunnar Martin Nicklasson CHM	Chairman	70	-
Kirsten Drejer BRD	Director/Board Member	69	2018-04-18
Bernadette Connaughton BRD	Director/Board Member	66	2019-04-03

Name	Weight	AuM	1st Jan change	Investor Rating
SIMPLIFY DEVELOPED EX-US PLUS DOWNSIDE CONVEXITY ETF - USD	0.01%	0 M€	-3.35%	-
RAREVIEW SYSTEMATIC EQUITY ETF - USD	0.00%	54 M€	+1.30%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
ZEALAND PHARMA A/S	-2.31%	-0.29%	+57.55%	+405.07%	6.87B
VERTEX PHARMACEUTICALS INCORPORATED	+1.21%	+2.09%	-2.99%	+84.59%	109B
REGENERON PHARMACEUTICALS, INC.	-1.68%	-4.93%	-26.98%	+10.94%	73.33B
ARGENX SE	-0.53%	-1.92%	+91.60%	+149.18%	39.83B
BIONTECH SE	-0.74%	-1.59%	+13.96%	-28.49%	26.83B
BEIGENE, LTD.	+2.31%	+13.80%	+31.48%	-16.43%	22.39B
WUXI APPTEC CO., LTD.	+5.72%	+5.38%	-25.18%	-49.52%	21.96B
NEUROCRINE BIOSCIENCES, INC.	+0.94%	+0.16%	+4.29%	+96.79%	14.5B
SUMMIT THERAPEUTICS INC.	+4.62%	+4.70%	+427.15%	+753.36%	14.03B
GENMAB A/S	+0.03%	-3.39%	-23.91%	-34.75%	13.37B
Average	+0.96%	+1.54%	+54.70%	+137.07%	34.18B
Weighted average by Cap.	+0.61%	+1.13%	+23.41%	+81.95%

	2024 *	2025 *
Net sales	347M 48.44M 46.58M 43.97M 39.38M 69.36M 4.18B 77.35M 534M 198M 1.72B 182M 178M 7.54B	2B 280M 269M 254M 227M 400M 24.1B 446M 3.08B 1.14B 9.94B 1.05B 1.03B 43.51B
Net income	-851M -119M -114M -108M -96.5M -170M -10.23B -190M -1.31B -485M -4.22B -445M -436M -18.48B	276M 38.54M 37.06M 34.99M 31.33M 55.18M 3.32B 61.54M 425M 158M 1.37B 145M 142M 6B
Net Debt	-7.12B -993M -955M -902M -808M -1.42B -85.63B -1.59B -10.96B -4.06B -35.33B -3.73B -3.65B -155B	-8.02B -1.12B -1.08B -1.02B -909M -1.6B -96.42B -1.79B -12.34B -4.57B -39.78B -4.19B -4.11B -174B